Bcl9L Antilichaam

Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF) -mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

283149

Q86UU0

NP_872363

Human

Unconjugated

Primary Antibodies

Cancer, Cell Cycle

Bcl9L Antibody is affinity chromatography purified via peptide column.

Cat. No. 1201 - HeLa Cell Lysate

1 mg/mL

Predicted species reactivity based on immunogen sequence: Mouse: (100%), Rat: (100%)

Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

Bcl9L antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG

Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

BCL9L

Cat. No. 17-001 - HeLa Cell Slide

B-cell CLL/lymphoma 9-like

Homo sapiens

Katoh M and Katoh M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. Int. J. Mol. Med. 2003; 12:643-9.

Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 2004; 64:8496-501.

Toya H, Oyama T, Ohwada S, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 2007; 98:484-90.

Deka J, Wiedemann N, Anderle P, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinoma. Cancer Res. 2010; 70:6619-28.

Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein

ELISA, WB, IHC-P, ICC, IF

32698936

Liquid